The Role of
Helicobacter pylori
IFN-γ
IL-4
Immune Response
OipA
Propolis
Journal
Galen medical journal
ISSN: 2322-2379
Titre abrégé: Galen Med J
Pays: Iran
ID NLM: 101625418
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
08
2019
revised:
22
12
2019
accepted:
24
01
2020
entrez:
1
9
2021
pubmed:
2
9
2021
medline:
2
9
2021
Statut:
epublish
Résumé
Regarding the important role of proinflammatory outer membrane protein (OipA) in the pathogenesis of The recombinant protein used in the present study corresponding to the The amounts of IL-4 and IFN-γ were significantly increased. The optimum concentration of OipA for the secretion of IL-4 was 5 μg/ml (P<0.0001). At higher concentrations, the amount of IL-4 diminished until suppression at 40 μg/mL. The optimum concentration of propolis, resulting in the most significant increased secretion of both IL-4 and IFN-γ was 40 μg/mL (P=0.0001 and P=0.0004). We found that an OipA concentration of 10 μg/mL was more effective for IFN-γ production; however, it was not effective for the high production of IL-4. Therefore, it is postulated that the OipA could mainly induce a Th1 response through the production of IFN-γ. We also observed propolis's capability to induce IFN-γ production; however, the effective concentration for this was the same as for IL-4. Therefore, as an adjuvant, proper concentration of propolis is required for OipA to give the optimum response.
Sections du résumé
BACKGROUND
BACKGROUND
Regarding the important role of proinflammatory outer membrane protein (OipA) in the pathogenesis of
MATERIALS AND METHODS
METHODS
The recombinant protein used in the present study corresponding to the
RESULTS
RESULTS
The amounts of IL-4 and IFN-γ were significantly increased. The optimum concentration of OipA for the secretion of IL-4 was 5 μg/ml (P<0.0001). At higher concentrations, the amount of IL-4 diminished until suppression at 40 μg/mL. The optimum concentration of propolis, resulting in the most significant increased secretion of both IL-4 and IFN-γ was 40 μg/mL (P=0.0001 and P=0.0004).
CONCLUSION
CONCLUSIONS
We found that an OipA concentration of 10 μg/mL was more effective for IFN-γ production; however, it was not effective for the high production of IL-4. Therefore, it is postulated that the OipA could mainly induce a Th1 response through the production of IFN-γ. We also observed propolis's capability to induce IFN-γ production; however, the effective concentration for this was the same as for IL-4. Therefore, as an adjuvant, proper concentration of propolis is required for OipA to give the optimum response.
Identifiants
pubmed: 34466568
doi: 10.31661/gmj.v9i0.1687
pmc: PMC8343919
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1687Informations de copyright
Copyright© 2020, Galen Medical Journal.
Références
Cell Microbiol. 2008 Apr;10(4):1008-20
pubmed: 18067607
Clin Microbiol Rev. 2010 Oct;23(4):713-39
pubmed: 20930071
Biochem Pharmacol. 2003 Dec 15;66(12):2281-9
pubmed: 14637186
Microbiol Immunol. 2012 Feb;56(2):85-92
pubmed: 22150716
Helicobacter. 2011 Sep;16 Suppl 1:26-32
pubmed: 21896082
J Immunol. 2004 Sep 1;173(5):3348-56
pubmed: 15322198
Gut. 2006 Sep;55(9):1360-1; author reply 1361
pubmed: 16905702
Clin Chim Acta. 2003 Dec;338(1-2):11-6
pubmed: 14637260
Comp Immunol Microbiol Infect Dis. 2003 Oct;26(5-6):329-41
pubmed: 12818620
Vet Parasitol. 2007 Mar 31;144(3-4):279-86
pubmed: 17113712
J Immunol. 2002 Dec 15;169(12):6977-84
pubmed: 12471132
Gut Liver. 2009 Jun;3(2):81-7
pubmed: 20431728
Proc Natl Acad Sci U S A. 2000 Jun 20;97(13):7533-8
pubmed: 10852959
Mem Inst Oswaldo Cruz. 2010 Nov;105(7):908-13
pubmed: 21120362
J Immunol. 2009 Jun 1;182(11):7085-101
pubmed: 19454706
Vaccine. 2007 Jan 26;25(7):1250-6
pubmed: 17084001
Dig Dis Sci. 1998 Jul;43(7):1482-7
pubmed: 9690382
Gut. 1995 Jun;36(6):831-3
pubmed: 7615268
Z Naturforsch C J Biosci. 2003 Jul-Aug;58(7-8):580-9
pubmed: 12939048
Gastroenterology. 2002 Aug;123(2):414-24
pubmed: 12145793
J Ethnopharmacol. 2007 Aug 15;113(1):1-14
pubmed: 17580109
Food Chem Toxicol. 1998 Apr;36(4):347-63
pubmed: 9651052
Vaccine. 2012 Aug 3;30(36):5310-5
pubmed: 22749593
Turk J Med Sci. 2016 Feb 27;47(1):326-333
pubmed: 28263510
Vaccine. 2014 Oct 21;32(46):6054-60
pubmed: 25236588
Helicobacter. 2016 Sep;21 Suppl 1:26-9
pubmed: 27531535